Clinical Trial Update: Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naive Adults 50 to 70 Years of Age [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and immunogenicity of the tetravalent dengue vaccine TV005 (TetraVax-DV) in flavivirus-naive adults aged 50-70; the study has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue

Drugs mentioned

• Tetravalent Dengue Vaccine TV005 (TetraVax-DV) (TV005)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Dengue | Phase 1 | Status: COMPLETED